<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260922071158N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-01</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Adding Lumbopelvic and Foot Core Stability Exercises to Conventional Physiotherapy in Patients with Knee Osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Adding Combined Lumbopelvic and Foot Core Stability Exercises to Conventional Physiotherapy on Pain, Function, Time to Clinically Meaningful Pain Response, and Sustainability of Treatment Effects in Patients with Knee Osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93551</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: After baseline assessments, participants will be randomly assigned to one of two groups (conventional physiotherapy or conventional physiotherapy plus lumbopelvic and foot core stability exercises). The randomization sequence will be generated using the online Sealed Envelope software with the Balanced Block Randomization method using blocks of four (to ensure balanced allocation between the two groups). For allocation concealment, the randomization sequence will be placed in opaque, sealed, and numbered envelopes, and each participant will receive one envelope in sequence after enrollment. The outcome assessor and participants will remain unaware of the envelope contents until allocation, Blinding description: Due to the nature of the intervention, blinding of participants and therapist is not feasible because the therapist is responsible for delivering the exercises and participants are aware of the type of intervention they receive. However, to reduce assessment bias, the outcome assessor will be independent from the therapist and will not be aware of group allocation. Therefore, this study will be designed and conducted as a single-blind trial in which the outcome assessor is blinded.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The same program as the control group, plus lumbopelvic and foot stabilization exercises. The combined lumbopelvic and foot stabilization program will be performed for 4 weeks, comprising 12 sessions (3 sessions per week), under physiotherapist supervision and in addition to usual physiotherapy. Foot stabilization exercises will be performed for both lower limbs.Lumbopelvic stabilization exercises will aim to improve trunk neuromuscular control, lumbopelvic stability, and lower-limb kinetic-chain control and will include the Abdominal Drawing-in Maneuver, Posterior Pelvic Tilt, Bridge, Supine Marching, Modified Dead Bug, Bird Dog, Modified Side Plank, half-squat, and Pallof Press. Foot stabilization exercises will aim to activate the intrinsic foot muscles, maintain the medial longitudinal arch, improve proprioception, and enhance functional foot stability and will include Short Foot Exercise, Toe Spread Out, Heel Raise, weight-shifting exercises, and double- and single-leg balance exercises on stable and unstable surfaces.Both programs will progressively advance from simple, low-challenge exercises to standing, single-leg, and functional activities. Progression will be based on individual tolerance, movement quality, and the ability to maintain appropriate alignment of the spine, pelvis, ankle, and knee. Throughout the program, emphasis will be placed on maintaining the medial foot arch and neutral spine and pelvic position, avoiding compensatory movements and dynamic knee valgus, and performing all exercises slowly and with controlled movement. Intervention 2: Control group: Transcutaneous electrical nerve stimulation will be applied for 20 minutes at 80 hertz, with a pulse width of 100 microseconds and tolerable sensory intensity, without muscle contraction. Electrodes will be placed around the medial and lateral aspects of the affected knee, with intensity adjusted as needed to maintain effective sensory stimulation.The exercise program will be performed for both lower limbs under physiotherapist supervision, three sessions per week for four weeks. It will include quadriceps isometric contraction, straight-leg raise, terminal knee extension, side-lying hip abduction, wall-supported mini-squat, and hamstring and gastrocnemius stretching. Exercise volume will progressively increase over the four weeks, with strengthening exercises progressing from 2 sets of 10 to 3 sets of 15 repetitions and stretching duration from 30 to 45 seconds.Progression will depend on pain, muscle soreness, movement quality, and individual tolerance. Exercises will be maintained or regressed if symptoms worsen or compensatory movements occur. Sessions will be stopped if severe pain, significant swelling, joint warmth, substantial range-of-motion limitation, or other safety concerns arise.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No further information is available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fateme Rahimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 5, Golestan Dormitory, Faculty of Rehabilitation Sciences, Iran University of Medical Sciences, Madadkaran Street, Shahid Shah Nazari Street, Madar Square, Mirdamad Boulevard, Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1545913487</zip>
        <telephone>+98 902 031 2352</telephone>
        <email>fatemerahimi7913@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Roya Khanmohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Rehabilitation Sciences, Iran University of Medical Sciences, Madadkaran Street, Shahid Shah Nazari Street, Madar Square, Mirdamad Boulevard, Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1545913487</zip>
        <telephone>+98 912 063 4056</telephone>
        <email>dr.rkhanmohammadi96@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Men and non-pregnant women
Age between 40 and 70 years
Diagnosis of primary symptomatic knee osteoarthritis confirmed by American College of Rheumatology clinical and radiographic criteria with knee pain, at least one osteophyte on radiography, at least one clinical criterion including age above 50 years, morning stiffness less than 30 minutes, or crepitus during active joint movement, and radiographic severity within Kellgren-Lawrence grade 2 or 3
Knee pain for more than 3 months with pain intensity of at least 3 out of 10 on the Visual Analogue Scale in the past week
Unilateral or bilateral knee osteoarthritis with the more painful knee selected as the study knee in case of bilateral involvement
Ability to walk independently without assistive devices such as cane or walker
Ability to read and write in Persian</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of other rheumatologic diseases, including rheumatoid arthritis, gout, spondyloarthropathies, or other inflammatory arthritis.
Significant effusion in the study knee
Presence of neurological, neuromuscular, or balance disorders affecting lower extremity function including stroke, Parkinson disease, radiculopathy, peripheral neuropathy, brain injury, or vestibular disorders
History of knee joint replacement in the study limb
Intra-articular injection in the study knee within the past 3 months including corticosteroid, hyaluronic acid, or platelet-rich plasma
Presence of acute lower extremity injury, fracture, or severe disabling low back pain within the past 6 months
Presence of severe obesity with body mass index greater than 35 kilograms per square meter
Presence of uncontrolled cardiovascular, pulmonary, or other systemic diseases that limit safe exercise performance
Presence of active cancer or history of cancer with risk of recurrence
Cardiac pacemaker or implanted cardiac defibrillator
Simultaneous participation in regular physiotherapy, rehabilitation, or knee-related exercise programs during the study period
Presence ofpain higher than 3 in other joints except the knee in the past week that could affect the study outcomes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The same program as the control group, plus lumbopelvic and foot stabilization exercises. The combined lumbopelvic and foot stabilization program will be performed for 4 weeks, comprising 12 sessions (3 sessions per week), under physiotherapist supervision and in addition to usual physiotherapy. Foot stabilization exercises will be performed for both lower limbs.Lumbopelvic stabilization exercises will aim to improve trunk neuromuscular control, lumbopelvic stability, and lower-limb kinetic-chain control and will include the Abdominal Drawing-in Maneuver, Posterior Pelvic Tilt, Bridge, Supine Marching, Modified Dead Bug, Bird Dog, Modified Side Plank, half-squat, and Pallof Press. Foot stabilization exercises will aim to activate the intrinsic foot muscles, maintain the medial longitudinal arch, improve proprioception, and enhance functional foot stability and will include Short Foot Exercise, Toe Spread Out, Heel Raise, weight-shifting exercises, and double- and single-leg balance exercises on stable and unstable surfaces.Both programs will progressively advance from simple, low-challenge exercises to standing, single-leg, and functional activities. Progression will be based on individual tolerance, movement quality, and the ability to maintain appropriate alignment of the spine, pelvis, ankle, and knee. Throughout the program, emphasis will be placed on maintaining the medial foot arch and neutral spine and pelvic position, avoiding compensatory movements and dynamic knee valgus, and performing all exercises slowly and with controlled movement.</i_keyword>
      <i_keyword>Control group: Transcutaneous electrical nerve stimulation will be applied for 20 minutes at 80 hertz, with a pulse width of 100 microseconds and tolerable sensory intensity, without muscle contraction. Electrodes will be placed around the medial and lateral aspects of the affected knee, with intensity adjusted as needed to maintain effective sensory stimulation.The exercise program will be performed for both lower limbs under physiotherapist supervision, three sessions per week for four weeks. It will include quadriceps isometric contraction, straight-leg raise, terminal knee extension, side-lying hip abduction, wall-supported mini-squat, and hamstring and gastrocnemius stretching. Exercise volume will progressively increase over the four weeks, with strengthening exercises progressing from 2 sets of 10 to 3 sets of 15 repetitions and stretching duration from 30 to 45 seconds.Progression will depend on pain, muscle soreness, movement quality, and individual tolerance. Exercises will be maintained or regressed if symptoms worsen or compensatory movements occur. Sessions will be stopped if severe pain, significant swelling, joint warmth, substantial range-of-motion limitation, or other safety concerns arise.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: before intervention, at the end of intervention, and one month after the end of intervention. Method of measurement: Visual Analogue Scale for Pain; this scale consists of a 10-centimeter line, with zero indicating “no pain” and 10 indicating “the worst pain imaginable.” Pain intensity is determined based on the average pain experienced over the previous seven days to reduce the influence of daily fluctuations in pain and provide a more stable estimate of the patient's pain intensity.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Total score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Timepoint: before intervention, at the end of intervention, and one month after the end of intervention. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index questionnaire and calculation of the total score according to the standard questionnaire scoring instructions.</sec_outcome>
      <sec_outcome>Number of repetitions of the 30-Second Chair Stand Test. Timepoint: before intervention, at the end of intervention, and one month after the end of intervention. Method of measurement: Counting the number of complete sit-to-stand repetitions from the chair within 30 seconds.</sec_outcome>
      <sec_outcome>Time to complete the 40-meter fast-paced walk test. Timepoint: before intervention, at the end of intervention, and one month after the end of intervention. Method of measurement: Recording the time required to walk the 40-meter path at maximum safe speed using a chronometer.</sec_outcome>
      <sec_outcome>Time to complete the four-step stair-climb test. Timepoint: before intervention, at the end of intervention, and one month after the end of intervention. Method of measurement: Recording the time required to ascend four stairs using a chronometer.</sec_outcome>
      <sec_outcome>Percentage of participants achieving a clinically meaningful improvement in pain. Timepoint: At the end of the intervention period (week 4). Method of measurement: The percentage of participants who achieve a reduction of at least 2 points in pain intensity from baseline, as measured using the Visual Analogue Scale, and maintain this reduction for at least three consecutive days at the end of the intervention period will be calculated. These participants will be classified as treatment responders, and the percentage of responders will be calculated for each group.</sec_outcome>
      <sec_outcome>Time to achieve a clinically meaningful improvement in pain. Timepoint: Daily from the initiation of the intervention through the end of week 4. Method of measurement: To evaluate the temporal pattern of pain changes and determine the speed of treatment response, pain intensity will be recorded daily during the four-week intervention period. Time to clinically meaningful pain improvement is defined as the time interval from the start of intervention to sustained achievement of the minimal clinically important change in pain intensity. In this study, the minimal clinically important change in pain is considered as a reduction of at least 2 points on the Visual Analogue Scale relative to the baseline value. Due to daily fluctuations in pain intensity, only the first day on which the pain reduction reaches the minimal clinically important change will not be considered as the treatment response time; rather, sustained achievement of treatment response will be recorded when a reduction of at least 2 points relative to baseline is maintained for at least three consecutive days.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-22</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Expressway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
